RNMT (RNA Guanine-7 Methyltransferase) Drug Discovery Landscape & Assay Solutions
- By admin
- 04 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Epitranscriptomic Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RNMT drug discovery. The table below integrates all unique product components from multiple candidates, ensuring broad modality support for research needs.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | RNMT Full-Length Recombinant Protein (His/GST tag, HEK293 expressed) | View RNMT Products |
| RAM (Co-factor) | RNMT-Activating Miniprotein (RAM) recombinant protein; co-expressed RNMT-RAM complex available for enzymatic assays | View RAM Products |
| Mutant Panel | Active site mutants (e.g., D368A, E397A) for selectivity and resistance screening, sequence verified by Mass Spec | View RNMT Products |
| Gene Delivery | RNMT Promise-ORF / Lentivirus (full-length ORF, CMV promoter, Puro selection, for stable cell lines) | View RNMT Products |
| Benchmark Ab | Anti-RNMT Recombinant Antibody (high-affinity positive control for Western Blot, IP, SPR, CETSA) | View RNMT Products |
| Validator | RNMT siRNA Set (3 unique sequences) for knockdown verification and assay specificity controls | View RNMT Products |
| Related Target: METTL3 | m6A methyltransferase; synergistic epitranscriptomic target for combination therapy | View METTL3 Products |
| Related Target: CMTR1 | Cap methyltransferase 1 (cap1 2'-O-MTase); downstream pathway extension target | View CMTR1 Products |
| Related Target: MYC | Oncogenic driver synergizing with mRNA capping machinery in MYC-driven cancers | View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Co-factor dependent activity (RNMT requires RAM for full methyltransferase activity) | Pre-formed RNMT-RAM complex available; co-expressed in HEK293, >95% purity, theoretical MW verified by SDS-PAGE/Mass Spec. |
| Structural integrity for HTS and crystallography | Native folding preserved; tag-free variants available at >5 mg/ml for crystallography; Endotoxin <1 EU/µg; high batch-to-batch consistency. |
| Cross-species preclinical bridging | Human/Mouse/Cyno RNMT ortholog recombinant proteins available with >95% purity, sequence verified, for toxicology and PK/PD bridging. |
| Drug resistance screening | Mutant panel (catalytic dead D368A, SAM-binding E397A, etc.) strictly sequence verified; enables early resistance profiling. |
| Lack of target engagement controls | High-affinity Anti-RNMT antibody included for CETSA, Western Blot, and immunoprecipitation. Validated siRNA for knockdown specificity checks. |
| SAM-dependent methyltransferase counter-screening | Homologous epitranscriptomic panel (METTL3, METTL14, CMTR1) strictly verified by mass spec for orthogonal selectivity assays. |
| False positives in cellular capping assays | Validated RNMT siRNA set (3 sequences) for rescue validation and specificity confirmation. |
Live RNMT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
- ➤ Latest Inhibitor Research
Global Clinical Landscape & Future Outlook
The race for RNMT therapeutics is intensifying, with major players shifting focus from traditional cytotoxics to targeted epitranscriptomic modulators. As first-generation small molecule inhibitors (SAM-competitive) advance through hit-to-lead optimization toward preclinical candidacy, the next wave of R&D is targeting allosteric disruption of the RNMT-RAM complex, combination regimens with CDK9/mTOR inhibitors and radiotherapy, and rational resistance mutation profiling. RNMT inhibition shows synthetic lethality in MYC-driven cancers and radioresistant tumors, making it a critical vulnerability in rapidly dividing cells and cancer stem cells. The field is also exploring PROTAC degraders and protein–protein interaction (PPI) inhibitors to overcome the limited selectivity of SAM-competitive molecules and to fully silence RNMT activity in high-turnover tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Merck (EMD Serono), Academic Spin-offs, Specialized Biotech | Solid Tumors (Breast, Prostate, Pancreatic, Glioblastoma), Hematologic Malignancies | Enzymatic Assay (high-purity RNMT-RAM complex with validated Km); SAM-competition & selectivity assays (WT vs mutant proteins). |
| PROTAC / Degrader | Emerging Oncology Startups, Discovery Pipeline | MYC-driven Cancers, Solid Tumors | Degradation Validation (high-affinity reference Abs); Ternary Complex Validation (high-purity antigen); stable cell lines for cellular stability assays. |
| PPI Inhibitor (RNMT-RAM disruption) | Research Institutes, Academic Centers | Refractory Solid Tumors, Radioresistant Tumors | Selectivity Assay (isolated RNMT and RAM proteins); SPR/BLI for binding kinetics. |
| Combination Therapy (w/ CDK9/mTOR/Radiation) | Translational Research Centers, Oncology Consortiums | Resistant/Refractory Tumors, MYC-amplified Tumors | Synergistic cell line models (Lentivirus + siRNA toolkit); viability assays with radiation or targeted agents. |
Additional Strategic Insights
For best-in-class RNMT inhibitors, selectivity over SAM-dependent methyltransferases (METTL3, PRMT5, DOT1L) is paramount—a >100x window is critical to avoid hematopoietic or neurological toxicity. Target engagement must be confirmed in live cells using CETSA with our high-affinity Anti-RNMT Antibody. Functional capping inhibition should be validated by cap0-specific mass spectrometry or anti-cap antibody assays. Finally, resistance profiling with active-site mutants (e.g., D368A, E397A) enables early structure-guided optimization and rational combination strategies.